Working Group Chair: Holly Posner, MD

In depth use of traditional and modern psychometric analyses (including Rasch analysis and various types of item-response theory) are becoming more common and can usher in a new era of robust clinical trial assessment and enhanced quality of decision-making.  All interested parties, including drug developers, regulatory authorities, key stakeholders, and academicians (clinicians, neuropsychologists, and psychometricians) need a common platform to evaluate and vet these methodologies side-by-side so that they may develop a common language and understanding for efficient and appropriate decision-making in drug development.  This dinner session will discuss these methods, the challenges for moving them forward into AD clinical trials, and will produce draft of recommendations for the next phase of research to accomplish this goal.